A- A A+

CDC Clinical Practice Guideline for Prescribing Opioids for Pain  United States, 2022.

Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. 

MMWR Recomm Rep 2022;71(No. RR-3):1–95. dx.doi.org/10.15585/mmwr.rr7103a1

https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm

USA. Medication-assisted Treatment (MAT): Statutes, Regulations, and Guidelines

Learn about the federal statutes, regulations, and guidelines that apply to medication-assisted treatment (MAT) for practitioners and opioid treatment programs (OTPs). (SAMHSA - Substance Abuse and Mental Health Services Administration, UA, zuletzt aufgerucfen am 04.11.2022)

https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines

EMCDDA. Health and social responses to drug problems: a European guide

Health and social responses to drug problems: a European guide examines some of the key public health challenges in the drugs field today and offers timely and practical advice to practitioners and policymakers for designing, targeting and implementing effective responses. The guide is composed of four sets of miniguides that look at responses to a range of drug problems in Europe. Framing the miniguides are two central resources: an action framework for developing responses and a set of strategies for successful implementation. Several spotlights frame issues cross-cutting the different components. (EMCDDA, Lissabon, Oktober 2022)

https://www.emcdda.europa.eu/publications/health-and-social-responses-a-european-guide_en

Schweiz. Berufsethischer Leitfaden für Heim- und Hausärzt:innen

Im Rahmen des Projektes «Ältere Menschen mit Abhängigkeit – Fachgerechte Betreuung und Behandlung» im Auftrag des Bundesamts für Gesundheit hat der Fachverband Sucht einen berufsethischen Leitfaden für Heim- und Hausärzt:innen erarbeitet. Die Inhalte resultieren aus einer Zusammenarbeit mit Fachpersonen aus der Suchtmedizin, der Hausarztmedizin, der Alterspsychiatrie und Pflegefachpersonen. (Fachverband Sucht, Schweiz, 2022)

https://fachverbandsucht.ch/de/news/berufsethischer-leitfaden-fur-heim-und-hausarztinnen

Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA? 

Russell C, Lange S, Kouyoumdjian F, Butler A, Ali F. 

Harm Reduct J. 2022 Aug 10;19(1):89. doi: 10.1186/s12954-022-00671-z. PMID: 35948961; PMCID: PMC9363267.

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-022-00671-z

Hospital Standards of Care for People with Substance Use Disorder. 

Englander H, Davis CS. 

N Engl J Med. 2022 Aug 20. doi: 10.1056/NEJMp2204687. Epub ahead of print. PMID: 35984354.

https://www.nejm.org/doi/full/10.1056/NEJMp2204687

Priority setting for Canadian Take-Home Naloxone best practice guideline development: an adapted online Delphi method. 

Ferguson M, Medley A, Rittenbach K, Brothers TD, Strike C, Ng J, Leece P, Elton-Marshall T, Ali F, Lorenzetti DL, Buxton JA. 

Harm Reduct J. 2022 Jul 2;19(1):71. doi: 10.1186/s12954-022-00650-4. PMID: 35780136; PMCID: PMC9250272.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250272/

Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. 

Calcaterra SL, Bottner R, Martin M, Englander H, Weinstein ZM, Weimer MB, Lambert E, Ronan MV, Huerta S, Zaman T, Ullal M, Peterkin AF, Torres-Lockhart K, Buresh M, O'Brien MT, Snyder H, Herzig SJ. 

J Hosp Med. 2022 Jul 26. doi: 10.1002/jhm.12908. Epub ahead of print. PMID: 35880821.

Abstract

https://pubmed.ncbi.nlm.nih.gov/35880821/

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. 

Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO

https://www.who.int/publications/i/item/9789240052390

Schottland. MAT Website Launched

The newly launched website will host medication-assisted treatment (MAT) and MAT Standard information and resources for all stakeholders. SDF will host and curate the site. (SDF – Scottish Drugs Forum, UK, 18.07.2022)

https://www.matstandards.co.uk/

DEA. Narcotic Treatment Program Manual 

United States Department of Justice, Drug Enforcement Administration, Diversion Control Division

A Guide to DEA Narcotic Treatment Program Regulations, Revised 2022

DEA-DC-056, EO-DEA169, June 15, 2022

https://files.constantcontact.com/55b56c59001/14d39109-3557-4d66-b169-d481256152f4.pdf

 

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. 

London: National Institute for Health and Care Excellence (NICE); 2022 Apr 20. PMID: 35609134.

https://www.ncbi.nlm.nih.gov/books/NBK580680/

Medicines associated with dependence or withdrawal symptoms: summary of NICE guideline 

Carville S, Lally M, Stannard C, Trewern L. 

BMJ 2022; 378 :o1454 doi:10.1136/bmj.o1454 

https://www.bmj.com/content/378/bmj.o1454

Schweiz. Neue Kapitel zu Opioid-Agonisten-Therapie auf alterundsucht.ch

06.07.22 / Die Wissensplattform «Alter und Sucht» richtet sich an Ärzt:innen, Fachpersonen aus der Suchthilfe und Pflege, die mit älteren Menschen zu tun haben, sowie ältere Menschen und deren Umfeld. Sie finden News, Praxisinstrumente, Konzepte, Fachpublikationen und Hinweise auf Veranstaltungen und Weiterbildungen.

Ab sofort sind auf der Webseite auch Themenkapitel zur Opioid-Agonisten-Therapie bei älteren Menschen für die Zielgruppen der Fachpersonen und Ärzteschaft verfügbar. Die Webinhalte wurden 2021 durch den Fachverband Sucht unter Einbezug von Expert:innen erarbeitet. Nebst aktuellen Informationen, bieten die Themenkapitel auch hilfreiche Links und Guidelines.

Die Versionen auf Französisch und Italienisch folgen im Laufe dieses Jahres. (Fachverband Sucht, Schweiz, 06.07.2022)

https://fachverbandsucht.ch/de/news/neue-kapitel-zur-opioid-agonisten-therapie-auf-alterundsuchtch

Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use. 

Sáiz PA, Flórez G, Arrojo M, Bernardo M, González-Pinto A, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, López A, Torrens M, Fonseca F, Tirado-Muñoz J, Arranz B, Garriga M, San L. 

Adicciones. 2022 Apr 1;34(2):157-167. English, Spanish. doi: 10.20882/adicciones.1548. PMID: 34171105.

https://adicciones.es/index.php/adicciones/article/view/1548

Buprenorphine Uptake During Pregnancy Following the 2017 Guidelines Update on Prenatal Opioid Use Disorder. 

Nguemeni Tiako MJ, Meinhofer A, Friedman A, South EC, Epstein RL, Meisel ZF, Morgan JR. 

Am J Obstet Gynecol. 2022 May 22:S0002-9378(22)00392-1. doi: 10.1016/j.ajog.2022.05.041. Epub ahead of print. PMID: 35613648.

https://www.ajog.org/article/S0002-9378(22)00392-1/pdf

Schottland. Medication Assisted Treatment (MAT) standards: access, choice, support

Evidence based standards to enable the consistent delivery of safe, accessible, high-quality drug treatment across Scotland. These are relevant to people and families accessing or in need of services, and health and social care staff responsible for delivery of recovery oriented systems of care. (Scottish Government, Population Health Directorate, Schottland, 31.05.2021)

https://www.gov.scot/publications/medication-assisted-treatment-mat-standards-scotland-access-choice-support/pages/6/

Scoping Review of Best Practice Guidelines for Care in the Labor and Birth Setting of Pregnant Women Who Use Methamphetamines. 

Gulbransen K, Thiessen K, Pidutti J, Watson H, Winkler J. 

J Obstet Gynecol Neonatal Nurs. 2022 Mar;51(2):141-152. doi: 10.1016/j.jogn.2021.10.008. Epub 2021 Dec 13. PMID: 34914926.

https://www.jognn.org/article/S0884-2175(21)00305-1/fulltext

The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. 

Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, Gordon AJ; VA/DoD Guideline Development Group*. 

Ann Intern Med. 2022 Mar 22. doi: 10.7326/M21-4011. Epub ahead of print. PMID: 35313113.

https://www.acpjournals.org/doi/full/10.7326/M21-4011

Schottland. National Wound Care Guide  - An introduction to recognising and assessing common wounds and injecting injuries in people who inject drugs

SDF – Scottish Drugs Forum, 2022

https://www.sdf.org.uk/wp-content/uploads/2022/02/National-Wound-Care-Guide.pdf

Expert Panel Consensus on Management of Advanced Cancer-Related Pain in Individuals With Opioid Use Disorder. 

Merlin JS, Khodyakov D, Arnold R, Bulls HW, Dao E, Kapo J, King C, Meier D, Paice J, Ritchie C, Liebschutz JM. 

JAMA Netw Open. 2021 Dec 1;4(12):e2139968. doi: 10.1001/jamanetworkopen.2021.39968. PMID: 34962565.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787463

Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. 

Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, Pacula RL, Rehm J, Room R, Brink WVD, Hall W. 

Int J Drug Policy. 2021 Aug 28:103381. doi: 10.1016/j.drugpo.2021.103381. Epub ahead of print. PMID: 34465496.

https://www.sciencedirect.com/science/article/pii/S0955395921002863

Telehealth for Opioid Use Disorder Toolkit: Guidance to Support High-Quality Care

The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. (PCSS – Providers Clinical Support Systems und SAMHSA - Substance Abuse and Mental Health Services, USA, 2.10.2021)

https://pcssnow.org/wp-content/uploads/2021/10/OUD-Toolkit_FINAL_10.2021.pdf

USA. Speaking the Same Language: A Toolkit for Strengthening Patient-Centered Addiction Care in the United States

Why this Toolkit? Why Now?

In the face of the ongoing substance use disorder (SUD) crisis and rising overdose deaths, policymakers and other stakeholders continue seeking ways for improving SUD prevention and treatment services.  While highly effective treatments for SUD are available, outcomes achieved in community settings rarely approach those that can be achieved in the best designed treatment systems.  Historically, there has been significant heterogeneity across states and communities in the organization and oversight of addiction treatment systems.  This has contributed to high variability in the quality of care and resulting patient outcomes. (ASAM – American Society of Addiction Medicine, November 2021)

https://www.asam.org/asam-criteria/toolkit

Schottland. New National Resource around Opioid Agonist Treatment 

A new National Resource has been created focusing on Opioid Agonist Treatment (OAT).

This resource fits under Medication Assisted Treatment (MAT), but is specific to Opiate replacement/agonist treatment. (Scottish Drug Deaths Taskforce, Schottland, 02.11.2021)

https://drugdeathstaskforce.scot/news/opioid-agonist-treatment-oat-guidance-for-scotland/

EMCDDA releases new European miniguides on responding to drug problems 

What are the most effective treatment options for cannabis problems? How to respond to new trends in cocaine use? How to help prevent the non-medical use of medicines?

These are among the questions explored in a new collection of miniguides being launched today by the EU drugs agency (EMCDDA). The miniguides — being released in four successive bundles between October 2021 and early 2022 — focus on patterns of use, harms, settings and vulnerable groups. Together, they make up the agency’s latest overview of actions and interventions now available to respond to the consequences of illicit drug use. (EMCDDA, Lisbon 18.10.2021 (News release No 9/2021))

https://www.emcdda.europa.eu/news/2021/9/emcdda-releases-new-european-miniguides-responding-drug-problems_en

Treating Concurrent Substance Use Among Adults 

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD). (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, September 2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-06-02-002.pdf

EMCDDA. Implementing quality standards for drug services and systems: a six-step guide to support quality assurance

Summary

This publication provides a practical introduction to the area of quality standards and quality assurance mechanisms and the key steps involved in their implementation in drug services and systems. The primary audience for this guide is those responsible for commissioning, planning or providing quality assurance processes at the national or local level. It may also be of interest to recipients of interventions, service users or advocacy groups. (EMCDDA, Lissabon, September 2021)

https://www.emcdda.europa.eu/system/files/publications/14065/TDMA21003ENN.pdf

Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. 

Lintzeris N, Dunlop A, Masters D (2019) 

NSW Ministry of Health, Sydney Australia

https://www.health.nsw.gov.au/aod/Publications/full-depot-bupe-interim-gl.pdf

USA. TIP 63: Medications for Opioid Use Disorder - Executive Summary

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, 10.08.2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-003.pdf